AllSci News
Hangzhou Sciwind's cAMP-biased GLP-1 ecnoglutide outperforms semaglutide in Phase II
Interim data from a Phase II head-to-head trial reported by China-based Hangzhou Sciwind Biosciences show that ecnoglutide (also known as XW003), the...
Autobahn on track for novel thyroid receptor agonist against bipolar depression after positive Phase II
San Diego-based Autobahn Therapeutics reported positive topline results from its Phase II AMPLIFY-BD trial of elunetirom (ABX-002) in bipolar depression,...
Pfizer's berobenatide demonstrates nearly 16% weight loss in Phase IIb obesity trial data
Pfizer (NYSE: PFE) presented detailed Phase IIb data at the American Diabetes Association's 86th Scientific Sessions showing that berobenatide (PF-3944;...
EU expands label for Chiesi’s Lojuxta to children with ultra-rare cholesterol disorder
The European Commission has approved an expanded indication for Italy-based Chiesi’s Lojuxta (lomitapide) to include children aged 5 years and older with…
Hopstem’s neural progenitor cell injection earns FDA RMAT designation for chronic stroke
Houston-based Hopstem Biotechnology announced receipt of a Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA for hNPC01, an iPSC-derived human…
China’s NMPA approves Vcare PharmaTech’s eratrectinib for NTRK fusion-positive solid tumors
China’s NMPA has granted marketing approval to eratrectinib (VC004), a next-generation TRK inhibitor developed by Nanjing-based Jiangsu Vcare PharmaTech Co., Ltd., for…
Bayer posts Phase III data showing Kerendia's kidney benefit in non-diabetic CKD
Bayer's finerenone (Kerendia), a non-steroidal mineralocorticoid receptor antagonist, delivered statistically significant improvements in kidney function...
Otsuka's Voyxact on course for full approval in IgA nephropathy after positive Phase III
Twelve-month eGFR data from the Phase III VISIONARY trial of sibeprenlimab (Voyxact) in IgA nephropathy show that Otsuka's anti-APRIL monoclonal antibody...
Gilead, Lakefront complete USD 2.175b acquisition of Ouro Med targeting BCMAxCD3 BsAb gamgeramig
Gilead Sciences (Nasdaq: GILD) and Belgium-based Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) have completed the joint acquisition of Ouro...
Stipple Bio partners with Lonza on multi-target ADC platform for precision oncology therapies
Cambridge, Massachusetts-based Stipple Bio, Inc. has entered a multi-target license agreement with Switzerland-based Lonza (SIX: LONN) to access the CDMO's...
Made Scientific and Pluristyx launch integrated iPSC development and manufacturing partnership
Princeton, New Jersey-based Made Scientific, Inc., a cell therapy contract development and manufacturing organization backed by South Korea's GC...
Pfizer signs up to access Chai Discovery's generative AI platform for next-gen antibody design
Pfizer (NYSE: PFE) has licensed San Francisco-based Chai Discovery's generative AI platform — including early access to Chai-3, a previously undisclosed...
Biogen’s once-yearly antisense oligonucleotide receives FDA BTD status for spinal muscular atrophy
Biogen (Nasdaq: BIIB) revealed that the US FDA has granted salanersen (BIIB115) Breakthrough Therapy Designation (BTD) for the treatment of spinal muscular…
Everest Medicines licenses Bejescin from Beijing Mabworks for Asia-Pacific commercialization
Everest Medicines (HKEX: 1952.HK) has secured exclusive rights to develop and commercialize Bejescin (MIL62, obinutuzumab beta injection) across the...
SOPHiA Genetics and Memorial Sloan Kettering form joint venture for precision oncology AI analytics
SOPHiA Genetics and Memorial Sloan Kettering move toward joint venture for precision oncology
The AllSci Brief
Systematic R&D and deal news. Daily.